C-Reveal Therapeutics was co-founded by Linden Lake, Mark Cobbold, MD, PhD, Cyril Benes, PhD, and Keith Flaherty, MD. It is developing proprietary selective and potent small molecule inhibitors of two targets identified and validated in the Lab of Mark Cobbold at Harvard Medical School and the Mass. General Hospital. These inhibitors disable a key novel tumor immune cloaking mechanism thus exposing the tumors to endogenous immune responses. C-Reveal’s drugs will be applicable to a broad spectrum of cancers and potentiate other cancer therapies such as checkpoint inhibitors, cancer vaccination, T Cell therapies and even traditional chemotherapy treatments.

Vesigen Therapeutics was founded by Robert Millman and Quan Lu, PhD at the Harvard T.H. Chan School of Public Health. Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Its patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Investors include Linden Lake, Bayer Leaps and Morningside Venture Investments. www.vesigentx.com

AexeRNA Therapeutics was co-founded by Linden Lake to develop novel mRNA therapeutics and vaccines, leveraging a proprietary high-potency next generation mRNA lipid nanoparticle delivery platform technology. The technology was developed by the late Prof. Mike Buschmann at George Mason University's Volgenau School of Engineering and National Center for Biodefense and Infectious Diseases and Prof. Drew Weisman at the University of Pennsylvania.

AexeRNA was acquired by BioNTech SE (NASDAQ: BNTX) in October 2023.